Novel parenteral vaccine formulations and uses thereof
    1.
    发明申请
    Novel parenteral vaccine formulations and uses thereof 审中-公开
    新型肠胃外疫苗制剂及其用途

    公开(公告)号:US20020051794A1

    公开(公告)日:2002-05-02

    申请号:US09925635

    申请日:2001-08-09

    申请人: ALK-ABELLO A/S

    CPC分类号: A61K39/39 A61K2039/55505

    摘要: Parenteral vaccine formulations and adjuvant compositions comprising certain salts as adjuvants are disclosed. Such parenteral vaccine formulations are used for generating an immune response in a subject following administration of the vaccine formulation or the adjuvant composition. Also disclosed is the use of these salts as adjuvants in parenteral vaccine formulations and adjuvant compositions, and to vaccine adjuvants comprising such salts.

    摘要翻译: 公开了肠胃外疫苗制剂和包含某些盐作为佐剂的佐剂组合物。 这种肠胃外疫苗制剂用于在施用疫苗制剂或佐剂组合物之后在受试者中产生免疫应答。 还公开了这些盐在肠胃外疫苗制剂和佐剂组合物中的用途以及包含这些盐的疫苗佐剂的用途。

    MUCOSOMAL ALLERGEN-SPECIFIC IMMUNOTHERAPY WITH INITIAL DOSING AFTER START OF POLLEN SEASON
    2.
    发明申请
    MUCOSOMAL ALLERGEN-SPECIFIC IMMUNOTHERAPY WITH INITIAL DOSING AFTER START OF POLLEN SEASON 审中-公开
    肉芽肿特异性免疫治疗在初次使用后开始使用

    公开(公告)号:US20140127298A1

    公开(公告)日:2014-05-08

    申请号:US14152753

    申请日:2014-01-10

    申请人: ALK-ABELLO A/S

    IPC分类号: A61K9/00 A61K39/35

    摘要: The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required.

    摘要翻译: 本发明涉及具有季节性变应原的粘膜变应原特异性免疫治疗,其中在季节性变应原的花粉季节开始后开始治疗。 优选地,季节性变应原以固体剂型提供,并且每天施用。 此外,有利地,在整个治疗期间可以使用相同的剂量,因为不需要向上剂量。

    RECOMBINANT ALLERGEN
    3.
    发明申请
    RECOMBINANT ALLERGEN 审中-公开
    重组过敏原

    公开(公告)号:US20130195902A1

    公开(公告)日:2013-08-01

    申请号:US13772046

    申请日:2013-02-20

    申请人: ALK-ABELLO A/S

    IPC分类号: C07K14/47

    摘要: Dander from the domestic cat (Felis domesticus) is one of the most common causes of IgE mediated allergy. The present invention relates to a recombinant folded Fel d 1 with molecular and biological properties similar to the natural counterpart and specifically a synthetic gene coding for a direct fusion of Fel d 1 chain 2 N-terminally to chain 1. E coli expression resulted in a non-covalently associated homodimer with an apparent molecular weight of 30 kDa defined by size exclusion chromatography, each 19177 Da subunit displayed a disulfide pattern identical to that found in the natural Fel d 1, and having identical fold of natural and recombinant Fel d 1. The, recombinant Fel d 1 provides for diagnosis and allergen specific immunotherapy of cat allergy.

    摘要翻译: 来自家猫(Felis homeus)的丹德斯是IgE介导的过敏最常见的原因之一。 本发明涉及具有类似于天然对应物的分子和生物学特性的重组折叠Fel d 1,特别涉及编码Fel d 1链2 N-末端与链1的直接融合的合成基因。大肠杆菌表达导致 通过大小排阻色谱法定义的具有30kDa表观分子量的非共价相关同源二聚体,每个19177Da亚基显示与天然Fel d 1中发现的相同的二硫图案,并具有天然和重组Fel d 1的相同折叠。 重组Fel d 1提供猫过敏的诊断和变应原特异性免疫治疗。

    Recombinant DNA encoding the major allergen of plantago lanceolata pollen, Pla I 1, and applications thereof
    4.
    发明申请
    Recombinant DNA encoding the major allergen of plantago lanceolata pollen, Pla I 1, and applications thereof 审中-公开
    编码番荔枝花粉主要变应原的重组DNA及其应用

    公开(公告)号:US20040071717A1

    公开(公告)日:2004-04-15

    申请号:US10161551

    申请日:2002-09-03

    申请人: ALK-ABELLO A/S

    摘要: A nucleic acid molecule encoding a peptide or protein comprising at least one epitope of the major allergen of Plantago lanceolata, Pla I 1, wherein the nucleic acid molecule a) has the sequence of SEQ ID NOS.: 5-7, b) is a fragment of the sequence SEQ ID NOS.: 5-7, c) has a sequence encoding the amino acid sequence of SEQ ID NO.: 8 or a fragment thereof, d) has a sequence hybridising to SEQ ID NOS.: 5-7 under stringent conditions, e) has a sequence derivable by degeneration of SEQ ID NOS.: 5-7, or f) a complementary strand of any of the sequences a)-e).

    摘要翻译: 编码肽或蛋白质的核酸分子,其包含Plantago lanceolata,Pla I的主要变应原的至少一个表位,其中所述核酸分子a)具有SEQ ID NO:5-7的序列,b)是 序列SEQ ID NO:5-7的片段,c)具有编码SEQ ID NO:8的氨基酸序列的序列或其片段,d)具有与SEQ ID NO:5-7杂交的序列 在严格条件下,e)具有可由SEQ ID NO:5-7的变性导出的序列,或f)序列a)-e)中任一序列的互补链。

    Allergen mutants
    9.
    发明申请
    Allergen mutants 审中-公开
    过敏原突变体

    公开(公告)号:US20040043438A1

    公开(公告)日:2004-03-04

    申请号:US10440516

    申请日:2003-05-16

    申请人: ALK-Abello A/S

    摘要: Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are mutants of naturally occurring allergens. The overall null-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof.

    摘要翻译: 公开了具有多重突变和降低的IgE结合亲和力的新型重组变应原。 过敏原是天然存在的变应原的突变体。 总体上,α-碳骨架三级结构基本保持不变。 还公开了制备这种重组变应原及其应用的方法。

    PLANT PROFILIN POLYPEPTIDES FOR USE IN NON-SPECIFIC ALLERGY IMMUNOTHERAPY
    10.
    发明申请
    PLANT PROFILIN POLYPEPTIDES FOR USE IN NON-SPECIFIC ALLERGY IMMUNOTHERAPY 审中-公开
    用于非特异性免疫缺陷病毒的植物型纤维蛋白多糖

    公开(公告)号:US20150126459A1

    公开(公告)日:2015-05-07

    申请号:US14391777

    申请日:2013-04-16

    申请人: ALK-Abello A/S

    IPC分类号: C07K14/415

    摘要: The invention relates to the treatment of a hypersensitivity immune response caused by a non-profilin allergen of a profilin-containing plant material (e.g. grass or tree pollen) by bystander suppression with a plant profilin (e.g. Phl p 12, Bet v 2, or Ole e 2) or a variant thereof. Also the invention features a particular variant of Phl p 12 with two of its cysteine residues replaced with another amino acid to increase its pharmaceutical properties.

    摘要翻译: 本发明涉及由植物profilin通过旁观者抑制(例如Phl p12,Bet v 2或或其它物质)治疗由含profilin的植物材料(例如草或树花粉)的非profilin变应原引起的超敏反应性免疫应答 Ole e 2)或其变体。 本发明还具有Phlp12的特定变体,其两个半胱氨酸残基被另一个氨基酸取代以增加其药物性质。